Pharmaceuticals

Gastroparesis Drugs Market Forecast 2026–2030 Presenting Long-Term Industry Insights

April 30, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Changes In Market Value Are Expected For The Gastroparesis Drugs Market Over The 2026–2030 Period?

The gastroparesis drugs market size has shown robust growth over recent years. It is forecasted to increase from $5.7 billion in 2025 to $6.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. This historic growth can be attributed to several factors, including the increasing diagnosis of diabetic gastroparesis, the established use of prokinetic and antiemetic drugs, the rising prevalence of diabetes-related gastrointestinal disorders, the availability of both over-the-counter and prescription medications for symptom relief, and the expansion of gastroenterology care services.

The gastroparesis drugs market is projected to experience substantial expansion over the coming years. By 2030, its valuation is anticipated to reach $7.37 billion, demonstrating a compound annual growth rate (CAGR) of 5.2%. This projected growth during the forecast period is driven by several factors, including the increasing global prevalence of diabetes, heightened recognition of gastroparesis as a chronic ailment, a greater need for effective long-term symptom management, broader availability of specialized gastrointestinal care, and the continuous requirement for enhanced motility-boosting treatments. Key developments expected in this period encompass an escalating dependence on prokinetic agents for managing symptoms, a rise in the application of combination drug therapies for gastroparesis, increasing requests for prescription-only gastroparesis medications, the proliferation of symptom-targeted treatment methodologies, and more widespread adoption of oral drug formulations for ongoing management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

Which Key Drivers Are Affecting The Gastroparesis Drugs Market Development?

The rising incidence of diabetes is projected to fuel the expansion of the gastroparesis drugs market in the coming years. This condition is a long-term metabolic ailment marked by high blood glucose levels, which stem from either inadequate insulin generation or inefficient insulin use. Several factors contribute to the increasing occurrence of diabetes, including inactive lifestyles, poor eating habits, genetic susceptibility, urbanization, an aging demographic, and expanding obesity figures. The gastroparesis drugs market plays a role in diabetes management by offering medicines that alleviate symptoms like nausea, vomiting, and slow stomach emptying, which are frequent digestive issues linked with diabetic gastroparesis. For example, data released in March 2024 by the Office for Health Improvement & Disparities, a UK-based government department, indicated that from March 2022 to March 2023, the number of individuals with type 1 diabetes receiving all eight recommended care processes experienced a 22% rise. Concurrently, type 2 diabetes patients showed a 21% increase, and the proportion reaching target HbA1c levels climbed to 37.9%, representing the highest figure ever recorded by the National Diabetes Audit. Consequently, the growing incidence of diabetes is propelling the expansion of the gastroparesis drugs market.

How Are Segments Identified Within The Gastroparesis Drugs Market Segment Framework?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

Which Trends Are Shaping Growth In The Gastroparesis Drugs Market?

Leading companies within the gastroparesis drugs market are concentrating on creating advanced solutions, including new prokinetic therapies, to enhance gastric motility and alleviate related symptoms. These novel prokinetic therapies represent fresh medications engineered to stimulate and boost the natural movement of the stomach and intestines, facilitating more efficient food passage. For example, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for the submission of Vanda’s New Drug Application (NDA) for tradipitant, intended for the management of gastroparesis symptoms. This specific approval concerns tradipitant, an investigational oral neurokinin-1 receptor antagonist, for addressing gastroparesis, which is a severe digestive ailment with significant unmet medical necessities. This acceptance represents a pivotal regulatory achievement for Vanda as the company proceeds with its efforts to gain marketing authorization for tradipitant in patients with gastroparesis.

Who Are The Companies Competing Within The Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Get The Full Gastroparesis Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Region Is The Leading Market For The Gastroparesis Drugs Market?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Gastroparesis Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2026, By The Business Research Company

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795